Minimization of administration route errors with subcutaneous rituximab

J Oncol Pharm Pract. 2016 Feb;22(1):186-7. doi: 10.1177/1078155214556010. Epub 2014 Oct 17.

Authors

Sarah Liptrott¹, Nathalie Cambon², Natalia Berthillon², Maria Mendoza², Rodney Smith²

Affiliations

¹ European Institute of Oncology, Milan, Italy sarah.liptrott@ieo.it.
² F. Hoffmann-La Roche Ltd, Basel, Switzerland.

No abstract available

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal, Murine-Derived / administration & dosage
Antineoplastic Agents / administration & dosage*
Humans
Infusions, Subcutaneous / methods
Rituximab / administration & dosage*

Substances

Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents
Rituximab